Anti-Mouse MHC Class I (H-2Kk) Antibody (AF3-12.1.3) 

Anti-Mouse MHC Class I (H-2Kk) Antibody (AF3-12.1.3) is a mouse-derived IgG1 type antibody inhibitor, targeting to mouse MHC Class I. Anti-Mouse MHC Class I (H-2Kk) Antibody (AF3-12.1.3) reacts with the mouse H-2Kk MHC class I alloantigen. Anti-Mouse MHC Class I (H-2Kk) Antibody (AF3-12.1.3) can be used for the researches of inflammation and immunology, such as obliterative airway disease^[1].

Mouse IgG1

Mouse IgG1 kappa, Isotype Control

Mouse

The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Mouse MHC Class I (H-2Kk) Antibody (AF3-12.1.3) (200 μg, intrabronchially administration, at days 1, 2, 3, 6 and weekly thereafter) induces obliterative airway disease in B10.A mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

in vivo administration

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

[Anti-Mouse MHC Class I (H-2Kk) Antibody (AF3-12.1.3)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Takenaka M, et al. Complement activation is not required for obliterative airway disease induced by antibodies to major histocompatibility complex class I: Implications for chronic lung rejection. J Heart Lung Transplant. 2012 Nov;31(11):1214-22.  [Content Brief]